Medicinal Chemistry Nature Reviews Drug Discovery
Kinase drug discovery, mapped across 25 years and every platform
- This review surveys the kinase landscape, tracing a shift from ATP-competitive small molecules to allosteric and covalent inhibitors, activators, proximity modulators, degraders and antibodies.
- Clinical-stage agents now touch nearly half of canonical human kinases, yet development clusters on a few blockbuster targets such as EGFR; over 150 approvals are reported.
- It also examines traits of successful agents and reasons for discontinuation and withdrawal.
Covering half the kinome sounds impressive, but clinical-stage is not validated: many of those kinases still lack a drug with proven efficacy. For a team choosing a target, the useful question is why the crowded ones stay crowded; my guess is tractable ATP pockets plus ready biomarkers. Sorting the discontinuations into selectivity-driven toxicity versus missing target dependency would show whether an allosteric or degrader route beats another ATP-competitive me-too.
Paper: Nature Reviews Drug Discovery ↗ The expansion of kinase drug discovery: new targets, platforms and indications